Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | USP9X | Q93008 | 3/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626539 | 0.86 | LMNA (0.43) | SCN5ASCN9ASMN1; SMN2GFERKMT2A | |
| SCHEMBL2625952 | 0.85 | SMN1; SMN2 (0.46) | TDP1SMN1; SMN2KMT2ALMNAMAPT | |
| SCHEMBL13147942 | 0.84 | OGA (0.39) | CHRM1TDP1SMN1; SMN2GFERKMT2A | |
| SCHEMBL13828266 | 0.82 | MAPT (0.45) | SMN1; SMN2GFERKMT2ALMNAMAPT | |
| SCHEMBL2626499 | 0.79 | SMN1; SMN2 (0.41) | TDP1SCN5ASCN9ASMN1; SMN2KMT2A | |
| SCHEMBL2626479 | 0.79 | SCN1A (0.49) | TDP1SCN5ASCN9ASMN1; SMN2KMT2A | |
| SCHEMBL2625857 | 0.78 | CYP3A4 (0.48) | CHRM1TDP1SCN5ASCN9AKMT2A | |
| SCHEMBL10310681 | 0.78 | CYP3A4 (0.48) | CHRM1TDP1SCN5ASCN9AKMT2A | |
| SCHEMBL2625962 | 0.77 | MAPT (0.47) | TDP1SCN5ASMN1; SMN2KMT2ALMNA | |
| SCHEMBL12710346 | 0.77 | MAPT (0.47) | TDP1SCN5ASMN1; SMN2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-8309587-B2 | Piperidine and piperazine phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, TRPA1, TRPV5 | CHRM1 2843/4885TDP1 3333/4885EGFR 3981/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | CHRM1 3255/4885TDP1 3758/4885EGFR 3328/4885 |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | CHRM1 3440/4885TDP1 4150/4885EGFR 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.